Regeneron stock gets Phase 2 POTS data for baloncibart
Published on 11/16/2026 at 14:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBaloncibart advances toward pivotal testing
- Regeneron's Phase 2 PINNACLE trial tested single doses of baloncibart in 82 adults with postural orthostatic tachycardia syndrome.
- The 450-milligram dose reduced the standing heart-rate response versus placebo through day 29 and improved selected patient-reported outcomes.
- Regeneron plans a potentially pivotal Phase 3 trial in the first half of 2027.
Regeneron announced Phase 2 PINNACLE results for baloncibart on November 12, 2026, according to the company's release. The investigational antibody targets natriuretic peptide receptor 1 in adults with postural orthostatic tachycardia syndrome, a condition marked by an abnormal rise in heart rate when standing.
Regeneron stock traded at 880.05 euros on Lang & Schwarz at 14:07 CET on Monday, November 16.
Phase 2 trial shows dose response
The randomized, double-blind trial enrolled 82 adults. Participants received a single subcutaneous dose of baloncibart at 150 milligrams or 450 milligrams, or placebo. The primary endpoint measured the change in heart rate from lying to standing on day 8.
The 450-milligram dose reduced that standing heart-rate change versus placebo by 11.4 beats per minute on day 8 and by 7.4 beats per minute on day 29. The 150-milligram dose produced a 9.5-beat reduction on day 8, but the effect was not maintained on day 29.
At day 29, the 450-milligram dose also improved reported orthostatic symptoms by 12.9 points and physical functioning by 13.8 points versus placebo. The change in activities of daily living was 8.7 points and did not reach the same statistical strength. Regeneron said the biomarker changes were consistent with the intended plasma-volume expansion from NPR1 blockade.
Safety profile and development plans
Single doses up to 450 milligrams were generally well tolerated. Treatment-emergent adverse events occurred in 48.1 percent of placebo recipients, 66.7 percent of patients receiving 150 milligrams and 67.9 percent of those receiving 450 milligrams. Two serious events occurred, involving headache in the 150-milligram group and syncope in the 450-milligram group; no event led to discontinuation.
The results are early clinical evidence rather than a regulatory decision. Regeneron said a potentially pivotal Phase 3 study is planned for the first half of 2027, giving investors a future development milestone for the POTS program. The company also cautioned that baloncibart's safety and efficacy have not been evaluated by a regulatory authority.
Regeneron Pharmaceuticals
- ISIN: US75886F1075
- Ticker: REGN
- Lang & Schwarz quote: 880.05 euros, November 16, 2026, 14:07 CET
- Clinical program: Baloncibart Phase 2 PINNACLE trial
The S&P 500 market environment provides the broader benchmark for US-listed biotechnology shares.
